ATE433997T1 - Verfahren zur herstellung von eptifibatid und relevante zwischenprodukte - Google Patents
Verfahren zur herstellung von eptifibatid und relevante zwischenprodukteInfo
- Publication number
- ATE433997T1 ATE433997T1 AT05735068T AT05735068T ATE433997T1 AT E433997 T1 ATE433997 T1 AT E433997T1 AT 05735068 T AT05735068 T AT 05735068T AT 05735068 T AT05735068 T AT 05735068T AT E433997 T1 ATE433997 T1 AT E433997T1
- Authority
- AT
- Austria
- Prior art keywords
- eptifibatide
- fragment
- producing
- intermediate products
- novel compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Combined Means For Separation Of Solids (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56045304P | 2004-04-08 | 2004-04-08 | |
PCT/US2005/011873 WO2005100381A2 (en) | 2004-04-08 | 2005-04-08 | Processes for preparing eptifibatide and pertinent intermediate compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE433997T1 true ATE433997T1 (de) | 2009-07-15 |
Family
ID=34956145
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05735068T ATE433997T1 (de) | 2004-04-08 | 2005-04-08 | Verfahren zur herstellung von eptifibatid und relevante zwischenprodukte |
AT09075233T ATE519781T1 (de) | 2004-04-08 | 2005-04-08 | Verfahren zur herstellung von eptifibatid und dazu betreffende zwischenverbindungen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT09075233T ATE519781T1 (de) | 2004-04-08 | 2005-04-08 | Verfahren zur herstellung von eptifibatid und dazu betreffende zwischenverbindungen |
Country Status (21)
Country | Link |
---|---|
US (2) | US7674768B2 (de) |
EP (2) | EP1735345B1 (de) |
JP (2) | JP4926942B2 (de) |
KR (1) | KR101238133B1 (de) |
CN (1) | CN1972960B (de) |
AT (2) | ATE433997T1 (de) |
AU (1) | AU2005233603B2 (de) |
CA (1) | CA2562157C (de) |
CY (2) | CY1109357T1 (de) |
DE (1) | DE602005014956D1 (de) |
DK (2) | DK1735345T3 (de) |
ES (2) | ES2369872T3 (de) |
HK (2) | HK1099313A1 (de) |
HR (2) | HRP20090490T1 (de) |
ME (2) | ME01063B (de) |
MX (1) | MXPA06011904A (de) |
PL (2) | PL2204383T3 (de) |
PT (2) | PT1735345E (de) |
RS (2) | RS51929B (de) |
SI (2) | SI2204383T1 (de) |
WO (1) | WO2005100381A2 (de) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1709065B1 (de) * | 2004-10-04 | 2010-06-02 | Novetide Ltd. | Gegenionenaustauschverfahren für peptide |
NL2000126C2 (nl) * | 2005-07-15 | 2008-01-29 | Solvay | Werkwijze voor de vervaardiging van eptifibatide. |
EP2245043A4 (de) * | 2008-02-06 | 2011-05-11 | Biocon Ltd | Verfahren zur reinigung eines peptids |
WO2009150657A1 (en) * | 2008-06-09 | 2009-12-17 | Natco Pharma Limited | Improved process for preparation of eptifibatide by fmoc solid phase synthesis |
CN101538314B (zh) * | 2009-01-13 | 2012-10-03 | 深圳翰宇药业股份有限公司 | 一种纯化爱啡肽的方法 |
CN101747412A (zh) * | 2009-12-30 | 2010-06-23 | 江苏诺泰制药技术有限公司 | 一种依替非巴肽的合成制备工艺 |
CN102174081B (zh) * | 2011-03-09 | 2013-05-29 | 杭州华津允上医药有限公司 | 埃替非巴肽及其前体的制备方法 |
CN102827249A (zh) * | 2011-06-14 | 2012-12-19 | 江苏豪森医药集团连云港宏创医药有限公司 | 一种依替巴肽的液相合成方法 |
CN103408637B (zh) | 2013-06-27 | 2015-12-02 | 深圳翰宇药业股份有限公司 | 一种爱啡肽的制备方法 |
CN104710509B (zh) * | 2013-12-11 | 2018-01-02 | 深圳翰宇药业股份有限公司 | 一种爱啡肽的制备方法 |
CN108250265A (zh) * | 2016-12-29 | 2018-07-06 | 北京中科亚光生物科技有限公司 | 一种合成含有分子内二硫键的多肽的新工艺 |
CN110894212B (zh) * | 2018-08-24 | 2021-06-04 | 翰宇药业(武汉)有限公司 | 一种合成依替巴肽硫醚的方法 |
CN109251234A (zh) * | 2018-10-08 | 2019-01-22 | 重庆科脉生物化工有限公司 | 一种抗血小板聚集药物爱啡肽的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2616785B1 (fr) * | 1987-06-19 | 1989-10-06 | Solvay | Composes guanidiniques comprenant un ion tetraphenylborate substitue et procede d'obtention de ces composes et utilisation des composes lors de la synthese peptidique |
US5318899A (en) * | 1989-06-16 | 1994-06-07 | Cor Therapeutics, Inc. | Platelet aggregation inhibitors |
US5686567A (en) * | 1989-06-16 | 1997-11-11 | Cor Therapeutics, Inc. | Platelet aggregation inhibitors |
US5747447A (en) * | 1992-04-30 | 1998-05-05 | Cor Therapeutics | Stable polypeptide composition |
BE1007184A3 (fr) * | 1993-06-18 | 1995-04-18 | Solvay | Procede de preparation d'un amide d'alpha-aminoacide, utilisable en synthese peptidique. |
US5688489A (en) * | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
MXPA04010910A (es) * | 2002-05-03 | 2005-01-25 | Avecia Ltd | Procedimiento para la sintesis de peptidos. |
DK1511761T3 (da) * | 2003-04-07 | 2006-11-27 | Novetide Ltd | Fremgangsmåde til fremstilling af cykliske peptider |
NL2000126C2 (nl) | 2005-07-15 | 2008-01-29 | Solvay | Werkwijze voor de vervaardiging van eptifibatide. |
-
2005
- 2005-04-08 KR KR1020067020842A patent/KR101238133B1/ko not_active IP Right Cessation
- 2005-04-08 JP JP2007507520A patent/JP4926942B2/ja not_active Expired - Fee Related
- 2005-04-08 WO PCT/US2005/011873 patent/WO2005100381A2/en active Application Filing
- 2005-04-08 RS RS20110463A patent/RS51929B/en unknown
- 2005-04-08 DE DE602005014956T patent/DE602005014956D1/de active Active
- 2005-04-08 SI SI200531388T patent/SI2204383T1/sl unknown
- 2005-04-08 PT PT05735068T patent/PT1735345E/pt unknown
- 2005-04-08 ME MEP-2009-347A patent/ME01063B/me unknown
- 2005-04-08 AT AT05735068T patent/ATE433997T1/de active
- 2005-04-08 CN CN2005800107525A patent/CN1972960B/zh not_active Expired - Fee Related
- 2005-04-08 PL PL09075233T patent/PL2204383T3/pl unknown
- 2005-04-08 AU AU2005233603A patent/AU2005233603B2/en not_active Ceased
- 2005-04-08 ME MEP-2011-175A patent/ME01260B/de unknown
- 2005-04-08 MX MXPA06011904A patent/MXPA06011904A/es active IP Right Grant
- 2005-04-08 DK DK05735068T patent/DK1735345T3/da active
- 2005-04-08 PT PT09075233T patent/PT2204383E/pt unknown
- 2005-04-08 CA CA2562157A patent/CA2562157C/en not_active Expired - Fee Related
- 2005-04-08 RS RSP-2009/0399A patent/RS51182B/sr unknown
- 2005-04-08 SI SI200530776T patent/SI1735345T1/sl unknown
- 2005-04-08 EP EP05735068A patent/EP1735345B1/de active Active
- 2005-04-08 PL PL05735068T patent/PL1735345T3/pl unknown
- 2005-04-08 DK DK09075233.8T patent/DK2204383T3/da active
- 2005-04-08 AT AT09075233T patent/ATE519781T1/de active
- 2005-04-08 ES ES09075233T patent/ES2369872T3/es active Active
- 2005-04-08 US US11/101,983 patent/US7674768B2/en not_active Expired - Fee Related
- 2005-04-08 EP EP09075233A patent/EP2204383B1/de active Active
- 2005-04-08 ES ES05735068T patent/ES2328713T3/es active Active
-
2007
- 2007-05-22 HK HK07105387.3A patent/HK1099313A1/xx not_active IP Right Cessation
-
2009
- 2009-09-07 CY CY20091100931T patent/CY1109357T1/el unknown
- 2009-09-15 HR HR20090490T patent/HRP20090490T1/xx unknown
- 2009-10-23 US US12/604,600 patent/US20100105609A1/en not_active Abandoned
-
2010
- 2010-12-30 HK HK10112216.1A patent/HK1145691A1/xx not_active IP Right Cessation
-
2011
- 2011-10-31 CY CY20111101038T patent/CY1111904T1/el unknown
- 2011-11-02 HR HR20110812T patent/HRP20110812T1/xx unknown
- 2011-12-06 JP JP2011266478A patent/JP2012111756A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE433997T1 (de) | Verfahren zur herstellung von eptifibatid und relevante zwischenprodukte | |
ATE486857T1 (de) | Verfahren zur herstellung von telmisartan | |
DE602006021411D1 (de) | Verfahren zur herstellung von optional 2-substituierten 1,6-dihydro-6-oxo-4-pyrimidincarboxylsäuren | |
ATE441627T1 (de) | Verfahren zur herstellung von valsartan | |
ATE515496T1 (de) | Verfahren zur herstellung von enantiomerenangereicherter indolin-2-carbonsäure | |
DE60316573D1 (de) | Verfahren und vorrichtung für die herstellung einer ein bituminöses bindemittel enthaltenden baumischung | |
ATE447567T1 (de) | Verfahren zur herstellung von tryptase- inhibitoren | |
DE60312029D1 (de) | Verfahren zur herstellung c-7 substituierter 5-androstene | |
DE60228724D1 (de) | Verfahren zur herstellung von beraprost und dessen salzen | |
ATE549315T1 (de) | Verfahren zur herstellung von kristallinem perindopril | |
ATE281434T1 (de) | Verfahren zur herstellung von benzoperhydroisoindolen | |
ATE388949T1 (de) | Verfahren zur herstellung von z-flupentixol | |
ATE502045T1 (de) | Verfahren zur herstellung von perindoprilerbumin | |
DE602004008486D1 (de) | Verfahren zur herstellung von (1s,4r)-cis-4-ä2-amino-6-chlor-9h-purin-9-ylü-2-cyclopenten-1-methanol | |
DE602004014822D1 (de) | Neues verfahren zur herstellung von nitrooxyderivaten von paracetamol | |
DE602005016857D1 (de) | Verfahren zur Herstellung von Tripeptid-Zwischenprodukten zur Herstellung von LHRH-Antagonisten | |
ATE515502T1 (de) | Verfahren zur herstellung von tetranorlabdanderivaten | |
DE602005004897D1 (de) | Verfahren zur Herstellung von i(2S, 3aR, 7aS)-octahydroindole-2-Carbonsäure und Umwandlung zum Trandolapril | |
DE50203388D1 (de) | Verbessertes verfahren zur herstellung von bisphosphiten | |
DE502006005580D1 (de) | Verfahren zur herstellung von optisch aktiven 3-phenylpropionsäurederivaten und folgeprodukte davon | |
DE502005003019D1 (de) | Verfahren zur herstellung der enantiomeren formen von 2,3-diaminopropionsäurederivaten | |
DE50312447D1 (de) | Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin | |
DE50304371D1 (de) | Technisches verfahren zur herstellung von tropenol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1735345 Country of ref document: EP |
|
UEP | Publication of translation of european patent specification |
Ref document number: 1735345 Country of ref document: EP |